π Big pharma giant Pfizer doubles down on failed cancer drug The US pharmaceutical behemoth is looking for a way to salvage its experimental drug Sigvotatug Vedotin - even though a key clinical trial failed to demonstrate survival benefits in patients with advanced, inoperable lung cancer, reports Bloomberg. Pfizer acquired the drug through its $43 billion purchase of Seagen, betting on a new class of treatments designed to deliver potent cancer-killing compounds directly to tumors. Now, the drugmaker is looking for ways to make that investment pay off. π Patients who received less chemotherapy before taking the drug lived over two months longer than others - possibly due to stronger immune systems, Jeff Legos, Pfizerβs chief oncology officer, argued at a European Society for Medical Oncology conference. The company is now testing its drug alongside Merck's cancer drug Keytruda in a Phase 3 trial involving patients with non-small cell lung cancer, hoping that combination will prove more effective. π Substack | Chat | @geopolitics_prime